Recent Operating Highlights: — Completed a $32 million capital raise to extend the runway through 2027. — Relocated into new, expanded headquarters in Mountain View, California. — Strengthened product development withNVIDIA Isaac Sim to accelerate innovation. — Continued expansion ofDriveMod deployments across multiple industries, including manufacturing, logistics, and CPG. — Integrated generative AI and AI […]
The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and increased awareness about bladder cancer and government initiatives aimed at promoting early detection and treatment. DelveInsight's Urothelial Carcinoma Market Insightsreport includes a comprehensive understanding of current treatment practices, urothelial carcinoma emerging
NEW YORK, NY / ACCESS Newswire / August 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of The J. M. Smucker Company ("The J. M. Smucker Company") (NYSE:SJM) concerning possible violations of federal securities laws. On June 9, 2025, Smucker announced its fourth quarter and full fiscal year 2025
NEW YORK, NY / ACCESS Newswire / August 6, 2025 / If you suffered a loss on your Fiserv, Inc. (NYSE:FI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fiserv-inc-lawsuit-submission-form?prid=160089&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
NEW YORK, NY / ACCESS Newswire / August 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Confluent, Inc. ("Confluent, Inc.") (NASDAQ:CFLT) concerning possible violations of federal securities laws. Confluent issued a press release on July 30, 2025, announcing its financial results for the second quarter of 2025 and
(NasdaqGM:RCKT), SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) — When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman RCKT Investors with Losses Encouraged to Contact Hagens Berman Before Aug. 11th Deadline GlobeNewswire August 06, 2025 SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) — When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ:
(NasdaqGM:FLY), CEDAR PARK, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) — Firefly Aerospace, a market leading space and defense technology company, today announced the pricing of its upsized initial public offering of 19,296,000 shares of its common stock at a public offering price of $45.00 per share. In addition, Firefly has granted the underwriters a 30-day
Firefly Aerospace Announces Pricing of Upsized Initial Public Offering GlobeNewswire August 06, 2025 CEDAR PARK, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) — Firefly Aerospace, a market leading space and defense technology company, today announced the pricing of its upsized initial public offering of 19,296,000 shares of its common stock at a public offering price of
A Texas judge has greenlighted a multi-state anti-trust climate initiatives lawsuit against major asset managers, says Friends of Science. The US DOE climate science report that rejects claims of a climate crisis is buried by the mainstream press. As reported by Reuters on Aug. 01, 2025, a US judge rejected efforts by Blackrock and other